Initiating Buprenorphine – A Certificate Training Program

The content for this activity is hosted at https://apha.docebosaas.com/learn. This site is used to administer the post-test, evaluation and credit for physicians only after viewing the content. 

Choose Register to complete the post-test, evaluation and claim credit. 

First time Users: If you have never completed training on this website, please select register in the upper right hand corner of the webpage.

    Course summary
    Available credit: 
    • 8.00 AMA PRA Category 1 Credit™
      The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
      • 8.00 Opioid Education
    Course opens: 
    10/16/2023
    Course expires: 
    10/16/2023
    Rating: 
    0

    The content for this program is hosted at https://apha.docebosaas.com/learn. 

    Module 1: Principles of Proper Pain Management (1.5 hours)
    Application-based
    SME: Emily Leppien
    Identify quantitative and qualitative strategies for comprehensive pain assessment.
    Discuss nonpharmacologic and pharmacologic options for multi-modal pain management.
    Describe appropriate methods to taper chronic opioid therapy as part of an interdisciplinary team.
    Develop an effective treatment plan given a patient case scenario.

    Module 2: Screening, brief intervention and interdisciplinary collaboration in SUD (1 hour)
    SME: Abby Cotton
    Recall signs and symptoms of SUD.
    Identify validated screening tools for substance use disorder.
    Recognize components of intervention planning along the continuum of SUD.
    Describe best practices in interdisciplinary collaboration for effective treatment of substance use disorder.

    Module 3: Pharmacologic Treatment for SUD (1.5 hours)
    Application-based
    SME: Haley Pals
    Describe the prevalence and long-term risks of AUD and OUD.
    Review evidence-based treatment options for AUD and OUD.
    Discuss considerations for management of polysubstance use.
    Construct a patient-specific pharmacotherapy plan for OUD.

    Module 4: The Intersection of Mental Health Conditions and SUD (30 minutes)
    SME: Jeffrey Gold
    Recognize the incidence of co-occurring mental health and substance use disorders.
    Outline potential treatments and services for individuals with co-occurring mental health and substance use disorders.

    Module 5: From Bystander to Advocate: Harm Reduction (1 hour)
    SME: Anita Jacobson
    Describe the impact of harm reduction efforts.
    Recognize barriers to seeking and receiving tools to promote harm reduction and recovery.
    Practice statements that can be used to express concern for patients with addiction and promote change behavior.
    Discuss strategies to engage patients in care related to substance use disorders.

    Module 6: The Self in Shame: Healing the Wounds of Substance Use Disorders (1 hour)
    SME: Jake Nichols
    Distinguish between the following terms: healthy shame, unhealthy shame, guilt and stigma.
    Explain how feelings related to shame can impact the treatment of substance use disorders and recovery process.  
    Describe how pharmacists can use the principles of healthy and unhealthy shame in assisting patients who are recovering or struggling with substance use disorders.

    Module 7: Addressing SDOH and Disparities in Pain Management (1 hour)
    SME: Laura Palombi
    Describe the relationship between social and economic determinants of health, risk for development of chronic pain and risk for inadequate pain management.
    Summarize ways that pharmacists and healthcare providers can reduce bias that contributes to health disparities in pain management. 
    Identify available tools and resources for pharmacists to address barriers to effective pain management. 

    Module 8: Legal Responsibilities in Buprenorphine Prescribing (30 minutes)
    SME: Michael Barnes
    Summarize current legislation allowing for pharmacists’ prescriptive authority of controlled substances.
    Identify legal requirements for prescribing buprenorphine.

    Conflict of Interest Disclosure:
    No members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients to disclose.

    Disclaimer Statement:
    The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

    In support of improving patient care, this activity has been planned and implemented by the University of Pittsburgh and the American Pharmacists Association. The University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician (CME)
    The University of Pittsburgh designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Opioid/Pain Management Credit
    This activity has been designated as and qualifies for Opioid/Pain Management Credit. It is the responsibility of the learner to maintain the educational presentation or conference agenda as evidence, if needed for audit purposes.

    Available Credit

    • 8.00 AMA PRA Category 1 Credit™
      The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
      • 8.00 Opioid Education
    Please login or register to take this course.

    The content for this activity is hosted at https://apha.docebosaas.com/learn. This site is used to administer the post-test, evaluation and credit for physicians only after viewing the content. 

    Choose Register/Complete Course to complete the post-test, evaluation and claim credit. 

    First time Users: If you have never completed training on this website, please select register in the upper right hand corner of the webpage.